<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02950428</url>
  </required_header>
  <id_info>
    <org_study_id>2015-01</org_study_id>
    <nct_id>NCT02950428</nct_id>
  </id_info>
  <brief_title>ACURATE Neo™ TA Delivery System in Patient With Severe Aortic Stenosis</brief_title>
  <official_title>ACURATE Neo™ Aortic Bioprosthesis for Implantation Using the ACURATE Neo™ TA Transapical Delivery System in Patients With Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symetis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to collect data pertaining to the safety and performance&#xD;
      of the ACURATE neo (TM) Aortic Bioprosthesis as implanted with the ACURATE neo (TM) TA&#xD;
      Transapical Delivery System. This device is intended for treatment of subjects with severe&#xD;
      aortic stenosis (AS) who have high risk for conventional aortic valve replacement (AVR)&#xD;
      surgery. The ACURATE neo (TM) Aortic Bioprosthesis is intended for use via minimally-invasive&#xD;
      transapical implantation in a well-defined population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, prospective, multicenter non randomised and open trial of the treatment&#xD;
      of patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via&#xD;
      open heart surgery is considered to be high risk. All patients will be followed up to 5 years&#xD;
      after the intervention.&#xD;
&#xD;
      The primary objective is to evaluate the safety and performance of the study device in&#xD;
      patients presenting with severe aortic stenosis considered to be high risk for surgery&#xD;
      Secondary objective is to evaluate adverse events and study device performance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 18, 2015</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">April 17, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety: freedom from all-cause mortality</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>freedom from all-cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Device Performance:Procedure success in absence of MACCE</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Procedure success in absence of MACCE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical endpoints according to the Valve Academic Research Consortium (VARC 2) guidelines</measure>
    <time_frame>30 Days and month 12</time_frame>
    <description>VARC 2 guidelines include different safety and efficacy endpoints like mortality, MI, stroke, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all cause mortality at 30 Days and 12 Months</measure>
    <time_frame>30 days and 12 months</time_frame>
    <description>Incidence of all cause mortality at 30 Days and 12 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from MACCE at 30 Days, 6 Months and 12 Months</measure>
    <time_frame>30 Days, 6 Months and 12 Months</time_frame>
    <description>Freedom from MACCE at 30 Days, 6 Months and 12 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who have a Procedural success defined by a combination of criteria</measure>
    <time_frame>procedure</time_frame>
    <description>Procedural success defined as ACURATE neo™ at intended location with</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of device success</measure>
    <time_frame>7 days/ Discharge, 30 Days, 6 Months and at 12 Months</time_frame>
    <description>Rate of device success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Functional Classification improvement</measure>
    <time_frame>30 Days, 6 Month and at 12 Months</time_frame>
    <description>NYHA Functional Classification improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment of valve performance (at 7 Days or Discharge, 30 Days, 6 Months, 12 Months) using a combination of measures</measure>
    <time_frame>7 Days or Discharge, 30 Days, 6 Months, 12 Months</time_frame>
    <description>Echocardiographic assessment of valve performance (at 7 Days or Discharge, 30 Days, 6 Months, 12 Months) using a combination of measures</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>ACURATE neo™TA Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™ TA Transapical Delivery System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACURATE neo™TA Delivery System</intervention_name>
    <description>ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk</description>
    <arm_group_label>ACURATE neo™TA Delivery System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 18 years old&#xD;
&#xD;
          2. Severe aortic stenosis defined as:&#xD;
&#xD;
               -  Mean aortic gradient &gt; 40 mmHg or&#xD;
&#xD;
               -  Peak jet velocity &gt; 4.0 m/s or&#xD;
&#xD;
               -  Aortic valve area of &lt; 0.8 cm2&#xD;
&#xD;
          3. High risk patient determined by a multidisciplinary heart team consensus (cardiologist&#xD;
             and cardiac surgeon) that patient is not a surgical candidate for conventional AVR due&#xD;
             to risk factors such as STS Score (8% or higher) or other co-morbid conditions&#xD;
             unrelated to aortic stenosis such as severe chronic obstructive pulmonary disease&#xD;
             (COPD), chest deformities and irradiated mediastinum&#xD;
&#xD;
          4. NYHA Functional Class &gt; II&#xD;
&#xD;
          5. Multidisciplinary heart team (cardiologist and cardiac surgeon) consensus that the&#xD;
             transapical approach is the most suitable access route for TAVI due to the presence of&#xD;
             the following anatomic conditions:&#xD;
&#xD;
               -  porcelain aorta or&#xD;
&#xD;
               -  severely calcified or highly tortuous peripheral vasculature not appropriate for&#xD;
                  transfemoral transcatheter aortic valve implantation or&#xD;
&#xD;
               -  vessels too small for retrograde approach or&#xD;
&#xD;
               -  other anatomical conditions making transapical approach more suitable&#xD;
&#xD;
          6. Aortic annulus diameter from ≥ 21mm up to ≤ 27mm by CT or TEE&#xD;
&#xD;
          7. Patient willing to participate in the study and provides signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Congenital unicuspid or bicuspid aortic valve or non-calcified&#xD;
&#xD;
          2. Extreme eccentricity of calcification&#xD;
&#xD;
          3. Severe mitral regurgitation (&gt; Grade 3)&#xD;
&#xD;
          4. Pre-existing prosthetic heart valve in any position and / or prosthetic ring&#xD;
&#xD;
          5. LV apex is not accessible via transapical access due to severe chest deformity&#xD;
&#xD;
          6. Previous surgery of the LV using a patch, such as the Dor procedure&#xD;
&#xD;
          7. Presence of apical LV thrombus&#xD;
&#xD;
          8. Calcified pericardium&#xD;
&#xD;
          9. Septal hypertrophy unacceptable for transapical procedure&#xD;
&#xD;
         10. Transesophageal echocardiogram (TEE) is contraindicated&#xD;
&#xD;
         11. ECHO evidence of intracardiac mass, thrombus, or vegetation&#xD;
&#xD;
         12. LVEF &lt; 20% by ECHO&#xD;
&#xD;
         13. Need for emergency intervention for any reason within 30 Days of scheduled procedure&#xD;
&#xD;
         14. Any percutaneous intervention, except for balloon valvuloplasty (BAV) within 1 month&#xD;
             prior to implant procedure&#xD;
&#xD;
         15. Untreated clinically significant coronary artery disease requiring revascularization&#xD;
             within 30 days before or after the study procedure&#xD;
&#xD;
         16. Acute myocardial infarction within 1 month prior to implant procedure&#xD;
&#xD;
         17. Previous TIA or stroke within 6 months prior to implant procedure&#xD;
&#xD;
         18. Active gastrointestinal (GI) bleeding within 3 months prior to implant procedure&#xD;
&#xD;
         19. Scheduled surgical or percutaneous procedure to be performed prior to 30 day visit&#xD;
&#xD;
         20. History of bleeding diathesis, coagulopathy, refusal of blood transfusions or severe&#xD;
             anemia (Hb&lt;8 g/dL)&#xD;
&#xD;
         21. Systolic pressure &lt;80mmHg, cardiogenic shock, need for inotropic support or IABP&#xD;
&#xD;
         22. Primary hypertrophic obstructive cardiomyopathy (HOCM)&#xD;
&#xD;
         23. Active infection or endocarditis&#xD;
&#xD;
         24. Hepatic failure (&gt; Child B)&#xD;
&#xD;
         25. Chronic renal dysfunction with serum creatinine &gt; 3.0 mg/dL or renal dialysis&#xD;
&#xD;
         26. Neurological disease severely affecting ambulation, daily functioning, or dementia&#xD;
&#xD;
         27. Life expectancy &lt; 12 months due to non-cardiac co-morbid conditions&#xD;
&#xD;
         28. Intolerance to aspirin, clopidogrel, contrast media, or porcine tissue and allergy to&#xD;
             nickel&#xD;
&#xD;
         29. Pregnant or breast-feeding women&#xD;
&#xD;
         30. For other severe illnesses of the patient (e.g. active carcinoma), the investigator&#xD;
             shall decide on an individual basis whether the patient is not to be included in the&#xD;
             study&#xD;
&#xD;
         31. Currently participating in an investigational drug or another device study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirko Pr Doss, Prof.Dr.Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abteilung Herzchirurgie Kerckhoff-Klinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhausbetriebsgesellschaft</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsched Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Luther University Halle Winttenberg</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>Aortic Stenosis</keyword>
  <keyword>transcatether Aortic Valve Implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-requests.html).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

